Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADI-PEG 20 plus low-dose cytarabine in older AML patients
NCT02875093Phase 1Terminated
- Sponsor
- Polaris Group
- Start
- Jan 2017
- Primary completion
- Jul 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Pegargiminase in acute myeloid leukemia (AML), sponsored by Polaris Group. Primary endpoint: Incidence of Treatment-Emergent Adverse Events. Started Jan 2017; status: terminated.
02
Drugs
Pegargiminase
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02875093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02875093.